NCT07094048 Immunoglobulins in Multiple Myeloma Patients Receiving a BCMA-Directed T Cell Engager
| NCT ID | NCT07094048 |
| Status | Recruiting |
| Phase | Phase 4 |
| Sponsor | CHU de Quebec-Universite Laval |
| Condition | Multiple Myeloma Refractory |
| Study Type | INTERVENTIONAL |
| Enrollment | 80 participants |
| Start Date | 2026-01-05 |
| Primary Completion | 2028-12 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
You will actively receive the study intervention — which may be a drug, biologic, device, or procedure.
Phase 4 studies follow an already-approved treatment in real-world conditions to monitor long-term safety and effectiveness.
This trial targets 80 participants in total. It began in 2026-01-05 with a primary completion date of 2028-12.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Bispecific antibody therapies targeting BCMA (B-cell maturation antigen) represent a novel therapeutic approach for patients with multiple myeloma. They are currently used in cases of refractory multiple myeloma but are also being investigated in earlier lines of treatment. However, these new therapies can lead to deeper immunosuppression and exacerbate an underlying immunosuppressive state in patients with multiple myeloma. As a result, infectious complications are common with these therapies and are a significant concern. Therefore, preventing infections in this population is crucial. However, data on the best strategies for prevention are currently lacking.
Eligibility Criteria
Inclusion Criteria: * Multiple myeloma patient: * ≥ 18 years old * ≥ 1 prior lines of therapy * Receiving a BCMA-directed T-cell Engager therapy (starting on treatment) * On previous Ig support or not Exclusion Criteria: * Less than 18 years old * Pregancy or breastfeeding
Contact & Investigator
Dr Julie Côté, MD,FRCPC
STUDY CHAIR
CHU de Québec-Université Laval
Frequently Asked Questions
Who can join the NCT07094048 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, studying Multiple Myeloma Refractory. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
What phase is the NCT07094048 trial and what does that mean for participants?
Phase 4 studies are conducted after a treatment has been approved. They monitor long-term safety and real-world effectiveness in a broader patient population.
Is NCT07094048 currently recruiting?
Yes, NCT07094048 is actively recruiting participants. Contact the research team at philippe.nadeau@chudequebec.ca for enrollment information.
Where is the NCT07094048 trial being conducted?
This trial is being conducted at Québec, Canada.
Who is sponsoring the NCT07094048 clinical trial?
NCT07094048 is sponsored by CHU de Quebec-Universite Laval. The principal investigator is Dr Julie Côté, MD,FRCPC at CHU de Québec-Université Laval. The trial plans to enroll 80 participants.